ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders.

The company is advancing innovative therapies for the treatment of currently unaddressed neurological complications of lysosomal storage disorders (LSDs), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Because most medications are unable to penetrate the blood-brain barrier (BBB), there is a clear unmet medical need to treat neurological complications of many diseases, including LSDs and neurodegenerative diseases. ArmaGen’s pipeline is based on decades of scientific leadership in engineering therapies to non-invasively penetrate the BBB, resulting in a unique and dominant intellectual property portfolio.

Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials. We are advancing our pipeline through licensing and collaboration agreements, in-house development efforts, and future partnering opportunities.

ArmaGen’s headquarters and research operations are located in Calabasas, CA.

ArmaGen CEO Mathias Schmidt provides an overview of the company’s mission, pipeline and technology.

“Our non-invasive approach to delivering therapies to the brain has the potential to revolutionize the treatment of devastating and currently unaddressed neurologic complications of serious diseases.”

Mathias Schmidt, Ph.D.
Chief Executive Officer